These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28288000)

  • 1. Age-associated chromatin relaxation is enhanced in Huntington's disease mice.
    Park M; Min B; Jeon K; Cho S; Park JS; Kim J; Jeon J; Song J; Kim S; Jeong S; Seo H; Kang YK
    Aging (Albany NY); 2017 Mar; 9(3):803-822. PubMed ID: 28288000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of H3K4me3 in Transcriptional Regulation Is Altered in Huntington's Disease.
    Dong X; Tsuji J; Labadorf A; Roussos P; Chen JF; Myers RH; Akbarian S; Weng Z
    PLoS One; 2015; 10(12):e0144398. PubMed ID: 26636336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic genetic interaction studies identify histone demethylase Utx as potential target for ameliorating Huntington's disease.
    Song W; Zsindely N; Faragó A; Marsh JL; Bodai L
    Hum Mol Genet; 2018 Feb; 27(4):649-666. PubMed ID: 29281014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model.
    van Hagen M; Piebes DGE; de Leeuw WC; Vuist IM; van Roon-Mom WMC; Moerland PD; Verschure PJ
    BMC Genomics; 2017 May; 18(1):373. PubMed ID: 28499347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of nucleosome dynamics in Huntington's disease.
    Stack EC; Del Signore SJ; Luthi-Carter R; Soh BY; Goldstein DR; Matson S; Goodrich S; Markey AL; Cormier K; Hagerty SW; Smith K; Ryu H; Ferrante RJ
    Hum Mol Genet; 2007 May; 16(10):1164-75. PubMed ID: 17403718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically.
    Dickey AS; Pineda VV; Tsunemi T; Liu PP; Miranda HC; Gilmore-Hall SK; Lomas N; Sampat KR; Buttgereit A; Torres MJ; Flores AL; Arreola M; Arbez N; Akimov SS; Gaasterland T; Lazarowski ER; Ross CA; Yeo GW; Sopher BL; Magnuson GK; Pinkerton AB; Masliah E; La Spada AR
    Nat Med; 2016 Jan; 22(1):37-45. PubMed ID: 26642438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remodeling of heterochromatin structure slows neuropathological progression and prolongs survival in an animal model of Huntington's disease.
    Lee J; Hwang YJ; Kim Y; Lee MY; Hyeon SJ; Lee S; Kim DH; Jang SJ; Im H; Min SJ; Choo H; Pae AN; Kim DJ; Cho KS; Kowall NW; Ryu H
    Acta Neuropathol; 2017 Nov; 134(5):729-748. PubMed ID: 28593442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic and transcriptional modulation of WDR5, a chromatin remodeling protein, in Huntington's disease human induced pluripotent stem cell (hiPSC) model.
    Baronchelli S; La Spada A; Ntai A; Barbieri A; Conforti P; Jotti GS; Redaelli S; Bentivegna A; De Blasio P; Biunno I
    Mol Cell Neurosci; 2017 Jul; 82():46-57. PubMed ID: 28476540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation profiling in human Huntington's disease brain.
    De Souza RA; Islam SA; McEwen LM; Mathelier A; Hill A; Mah SM; Wasserman WW; Kobor MS; Leavitt BR
    Hum Mol Genet; 2016 May; 25(10):2013-2030. PubMed ID: 26953320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
    Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
    J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
    Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
    J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wheel running and environmental enrichment differentially modify exon-specific BDNF expression in the hippocampus of wild-type and pre-motor symptomatic male and female Huntington's disease mice.
    Zajac MS; Pang TY; Wong N; Weinrich B; Leang LS; Craig JM; Saffery R; Hannan AJ
    Hippocampus; 2010 May; 20(5):621-36. PubMed ID: 19499586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
    Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
    J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy.
    Chang R; Liu X; Li S; Li XJ
    Drug Des Devel Ther; 2015; 9():2179-88. PubMed ID: 25931812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.
    Weydt P; Pineda VV; Torrence AE; Libby RT; Satterfield TF; Lazarowski ER; Gilbert ML; Morton GJ; Bammler TK; Strand AD; Cui L; Beyer RP; Easley CN; Smith AC; Krainc D; Luquet S; Sweet IR; Schwartz MW; La Spada AR
    Cell Metab; 2006 Nov; 4(5):349-62. PubMed ID: 17055784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Htt CAG repeat expansion confers pleiotropic gains of mutant huntingtin function in chromatin regulation.
    Biagioli M; Ferrari F; Mendenhall EM; Zhang Y; Erdin S; Vijayvargia R; Vallabh SM; Solomos N; Manavalan P; Ragavendran A; Ozsolak F; Lee JM; Talkowski ME; Gusella JF; Macdonald ME; Park PJ; Seong IS
    Hum Mol Genet; 2015 May; 24(9):2442-57. PubMed ID: 25574027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
    Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
    Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenic Huntington Alters BMP Signaling and Synaptic Growth through Local Disruptions of Endosomal Compartments.
    Akbergenova Y; Littleton JT
    J Neurosci; 2017 Mar; 37(12):3425-3439. PubMed ID: 28235896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific promoter deacetylation of histone H3 is conserved across mouse models of Huntington's disease in the absence of bulk changes.
    Guiretti D; Sempere A; Lopez-Atalaya JP; Ferrer-Montiel A; Barco A; Valor LM
    Neurobiol Dis; 2016 May; 89():190-201. PubMed ID: 26851501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT.
    Moreno CL; Ehrlich ME; Mobbs CV
    Neurobiol Dis; 2016 Jan; 85():25-34. PubMed ID: 26485309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.